Clinical Trial Update: Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage [Phase 1]

View source ↗

Summary

Phase 1 trial evaluate safety and tolerability of PF-05230907 in intracerebral hemorrhage; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage

Drugs mentioned

• PF-05230907

Snippet

Sponsor: Pfizer | Conditions: Intracerebral Hemorrhage | Phase 1 | Status: TERMINATED | Results posted: 2019-04-17